Related Experiment Videos

Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke

Mark Willmot1, Lian Zhao, Stan Heptinstall

  • 1University of Nottingham, Institute of Neurosciences, Nottingham, United Kingdom.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|October 2, 2007
PubMed

Insights

Triple antiplatelet therapy, combining aspirin, dipyridamole, and clopidogrel, shows promise for preventing recurrent ischemic strokes. This approach may be superior to single or dual antiplatelet agents in select patients, though further safety and efficacy trials are needed.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet agents are crucial for secondary stroke prevention.
  • Recurrent ischemic strokes can occur despite standard single or dual antiplatelet therapy.
  • Laboratory studies suggest triple antiplatelet therapy enhances inhibition of platelet and leucocyte function.

Purpose of the Study:

  • To evaluate the efficacy of triple antiplatelet therapy in patients experiencing recurrent ischemic strokes.
  • To assess the response to a combination of aspirin, dipyridamole, and clopidogrel.

Main Methods:

  • Case report of a 69-year-old male patient with recurrent strokes.
  • Retrospective analysis of 8 additional patients treated with triple antiplatelet therapy.
  • Follow-up period of 28 months for the patient series.

Main Results:

  • The index patient responded to triple antiplatelet therapy (aspirin, dipyridamole, clopidogrel) after failure of single/dual therapy.
  • Triple antiplatelet therapy was effective in 8 additional patients over 28 months.
  • Laboratory studies indicate superior platelet and leucocyte inhibition with triple therapy.

Conclusions:

  • Triple antiplatelet therapy may offer a viable option for secondary stroke prevention in specific patient populations.
  • Clinical trials are necessary to establish the safety and efficacy of this combination therapy.
  • Risk of major bleeding must be carefully considered and evaluated in future studies.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...